Sohah Iqbal, MD
Interventional Cardiology · Salem, MANPI 1992902555
Payments from drug & device makers
Across 10 payments — averaging $453.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Radux Devices LLC$4K
- Penumbra, Inc.$134
- ZOLL Circulation Inc$121
- AstraZeneca$109
- Abiomed$95
- Biotronik Inc.$41
- plus $33 from 2 others
What the payments were for
- Consulting fees$4,00088%
- Food & beverage$53312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Radux Devices LLC | 1 | $4,000 |
| Penumbra, Inc. | 2 | $134 |
| ZOLL Circulation Inc | 1 | $121 |
| AstraZeneca | 1 | $109 |
| Abiomed | 1 | $95 |
| Biotronik Inc. | 2 | $41 |
| Medtronic | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo$125
- TherOx DS2 Console$121
- Catheter$121
- Downstream Cartridge$121
- BRILINTA$109
How this compares
$4,533 in reported general payments places this provider in the 45th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $75,544 |
| Repatha SureclickEvolocumab | 12 | $15,826 |
| Praluent PenAlirocumab | 13 | $7,760 |
| Metoprolol Succinate | 174 | $2,740 |
| Rosuvastatin Calcium | 87 | $2,487 |
| Atorvastatin Calcium | 149 | $1,973 |
| Ezetimibe | 32 | $1,384 |
| ClopidogrelClopidogrel Bisulfate | 21 | $401 |
| Lisinopril | 46 | $396 |
| Losartan Potassium | 43 | $382 |
| Amlodipine Besylate | 56 | $331 |
| Furosemide | 36 | $202 |
| Simvastatin | 13 | $130 |
| Nitroglycerin | 12 | $127 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 14 | $118 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Salem
- Charles GibsonBoston$16.3M
- Eric SecemskyBoston$7.3M
- Duane PintoBoston$4.2M
- Suzanne BaronBoston$3.9M
- Pinak ShahBoston$3M
- Robert YehBoston$2.1M
- Jeffrey PopmaBoston$1.9M
- Roger LahamBoston$1.2M
- Farouc JafferBoston$900K
- Nikolaos KakourosWorcester$867K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.